<DOC>
	<DOCNO>NCT02246868</DOCNO>
	<brief_summary>The main objective study compare first second recovery assessment recovery subject change batch ass whether haemostasis achieve Optivate® treat bleed . The secondary objective evaluate clinical tolerance safety Optivate® .</brief_summary>
	<brief_title>An Open Study Investigate Safety Efficacy Optivate® Severe Haemophilia A Patients .</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Immunocompetent severe Haemophilia A without inhibitor FVIII , least 12 year age , currently receive FVIII concentrate 150 exposure . Subjects require elective surgergy within 6 month start OPTIVATE® permit include study provide surgery could perform use OPTIVATE® FVIII cover .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>